Cross-Sectional Study of Patients With Onset of Acute Coronary Syndrome During Statin Therapy

Nobuhiro Akuzawa a, c, Takashi Hatori b, Kunihiko Imai a, Yonosuke Kitahara a, Masahiko Kurabayashi b

Abstract

Background: Although statin therapy significantly reduces cardiovascular morbidity and mortality, atherosclerotic plaque progresses in some patients taking statins. This study investigated the factors associated with onset of acute coronary syndrome (ACS) early after the initiation of statin therapy.

Methods: Consecutive patients taking statins who presented with ACS (n = 64) were divided into < 1-year and > 1-year groups based on the duration of statin therapy. Patient characteristics, coronary risk factors, lesion locations, and percutaneous intervention procedures were compared between groups.

Results: The < 1-year group was significantly younger (57.6 ± 11.9 years vs. 76.6 ± 9.1 years, P < 0.01), had significantly higher body mass index (27.22 ± 4.20 kg/m² vs. 24.60 ± 4.65 kg/m², P < 0.05), higher proportion of males (94% vs. 70%, P < 0.05), higher proportion of current smokers (61% vs. 17%, P < 0.01), and lower proportions taking aspirin and calcium antagonists (both 17% vs. 57%, P < 0.05) than the > 1-year group. In the < 1-year group, there were significant correlations between the low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels (r = 0.649, P = 0.004) and between the TG and hemoglobin (Hb)A1c levels (r = 0.552, P = 0.018), but these correlations were not observed a year before admission. TG level was the only parameter associated with LDL-C and HbA1c levels.

Conclusions: A linear correlation between the LDL-C and TG levels, obesity, older age, male sex, and smoking may be associated with increased risk of onset of ACS early after the initiation of statin therapy. Prospective cohort studies are needed to further explore these interactions.

Keywords: Acute coronary syndrome; Low-density lipoprotein cholesterol; Statin; Triglyceride

Introduction

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, known as statins, are effective for both primary and secondary prevention of cardiovascular disease (CVD) [1, 2]. Statins decrease the low-density lipoprotein cholesterol (LDL-C) level, and have anti-inflammatory and immunomodulatory effects on atherosclerotic plaque [3-5].

In patients undergoing intensive lipid-lowering therapy with atorvastatin, decreased coronary plaque volume showed a significant positive correlation with the percent decrease in LDL-C level [6]. Some studies that used virtual histology-intravascular ultrasound to follow patients found that coronary plaque regression after statin treatment correlated with a prominent decrease in the fibrofatty component within a few weeks and lasted for 8 - 9 months [7-10]. However, coronary plaques may progress despite early statin treatment and a subsequent low LDL-C level in patients with acute coronary syndrome (ACS) [7]. The specific lipid profiles associated with plaque progression despite statin therapy are currently unclear.

The primary objective of this study was to investigate the risk factors and lipid profiles in patients with onset of ACS < 1 year after the initiation of statin therapy.

Materials and Methods

Subjects

A total of 167 patients (119 males and 48 females) who underwent emergent percutaneous coronary intervention (PCI) after admission to our hospital with their first presentation of ACS between January 2009 and December 2013 were identified in our department database. Sixty-four of these patients (49 males and 15 females) were taking statins at admission, and were included in this study. The study was approved by the Gunma Chuo Hospital Ethics Committee. Written informed consent for inclusion in the study was obtained from all en-
Patients were divided into two groups according to the period of statin therapy before admission for ACS: a < 1-year group (n = 18) and a > 1-year group (n = 46). All patients complained of chest pain or discomfort at rest within 48 h before admission, and had been diagnosed with a high LDL-C level (≥ 140 mg/dL) before statin administration. The infarct type was classified as ST-elevation myocardial infarction if there were both ST segment elevation on electrocardiography and an increase in the serum troponin I level to ≥ 0.05 ng/mL, or

|                    | < 1-year statin therapy (n = 18) | > 1-year statin therapy (n = 46) | P    |
|--------------------|----------------------------------|----------------------------------|------|
| Age (years)        | 57.6 ± 11.9                      | 76.6 ± 9.1**                     | < 0.001** |
| Male/female        | 17/1 (94/6)*                     | 32/14 (70/30)                   | 0.030* |
| BMI                | 27.22 ± 4.20*                    | 24.60 ± 4.65                    | 0.016* |
| Disease type       |                                  |                                  |      |
| STEMI              | 9 (50)                           | 30 (65)                          | 0.262 |
| NSTE-ACS           | 9 (50)                           | 16 (35)                          | 0.262 |
| Risk factors       |                                  |                                  |      |
| Diabetes mellitus  | 8 (44)                           | 22 (48)                          | 0.807 |
| Hypertension       | 9 (50)                           | 34 (74)                          | 0.067 |
| Hyperuricemia      | 3 (17)                           | 4 (9)                            | 0.305 |
| Hypertriglyceridemia| 4 (22)                           | 7 (15)                           | 0.370 |
| Current smoking    | 11 (61)**                        | 8 (17)                           | 0.001** |
| Associated diseases|                                  |                                  |      |
| History of CI      | 2 (11)                           | 20 (43)*                         | 0.014* |
| History of AF      | 1 (6)                            | 6 (13)                           | 0.358 |
| Medications        |                                  |                                  |      |
| Aspirin            | 3 (17)                           | 26 (57)**                        | 0.004** |
| Clopidogrel        | 0 (0)                            | 3 (7)                            | 0.364 |
| Ticlopidine        | 0 (0)                            | 3 (7)                            | 0.364 |
| Warfarin           | 1 (6)                            | 3 (7)                            | 0.687 |
| ARB/ACEI           | 11 (61)                          | 27 (59)                          | 0.860 |
| β-blocker          | 1 (6)                            | 7 (15)                           | 0.277 |
| Calcium antagonist | 3 (17)                           | 26 (57)**                        | 0.004** |
| Sulfonylurea       | 3 (17)                           | 7 (15)                           | 0.579 |
| Insulin            | 3 (17)                           | 8 (17)                           | 0.630 |
| Strong statins     | 16 (89)**                        | 22 (48)                          | 0.003** |
| Atorvastatin       | 3 (17)                           | 10 (22)                          | 0.470 |
| Pitavastatin       | 5 (27)                           | 5 (11)                           | 0.101 |
| Rosuvastatin       | 8 (44)*                          | 7 (15)                           | 0.018* |
| Standard statins   | 2 (12)                           | 24 (52)**                        | 0.003** |
| Fluvastatin        | 1 (6)                            | 7 (15)                           | 0.277 |
| Pravastatin        | 1 (6)                            | 12 (26)                          | 0.061 |
| Simvastatin        | 0 (0)                            | 5 (11)                           | 0.180 |
| Duration of statin therapy (years) | 0.61 ± 0.27** | 8.35 ± 4.65 | < 0.001** |

Values are n (%) or mean ± SD. *P < 0.05, **P < 0.01. BMI: body mass index; STEMI: ST-elevation myocardial infarction; NSTE-ACS: non-ST elevation acute coronary syndrome; CI: cerebral infarction; AF: atrial fibrillation; ARB: angiotensin-receptor blocker; ACEI: angiotensin-converting enzyme inhibitor.

Clinical and laboratory findings

Patients were divided into two groups according to the period of statin therapy before admission for ACS: a < 1-year rolled patients.
non-ST elevation ACS in all other cases. Known coronary risk factors including diabetes mellitus, dyslipidemia, hypertension, hyperuricemia, and current smoking were determined by interview and by review of the medical notes. Patients were also screened for previously undiagnosed disease as follows. Hypertension was diagnosed if the systolic blood pressure was > 140 mm Hg or diastolic blood pressure was > 90 mm Hg, according to the Japanese Society of Hypertension guidelines for the management of hypertension (JSH2014) [11]. Dyslipidemia was diagnosed if the triglyceride (TG) level was ≥ 150 mg/dL, the high-density lipoprotein cholesterol (HDL-C) level was < 40 mg/dL, or the LDL-C level was ≥ 140 mg/dL, according to the Japan Atherosclerosis Society guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases, 2012 version [12]. Hyperuricemia was diagnosed if the uric acid (UA) level was ≥ 7.0 mg/dL, according to the Japanese guideline for the management of hyperuricemia and gout [13]. Diabetes mellitus was diagnosed if the hemoglobin (Hb) A1c level was ≥ 6.5% in addition to a fasting plasma glucose level of ≥ 126 mg/dL, or a 75-g oral glucose tolerance test 2-h glucose level of ≥ 200 mg/dL, or a random glucose level of ≥ 200 mg/dL, according to the Japan Diabetes Society evidence-based practice guideline for the treatment of diabetes in Japan 2013 [14]. The HDL-C, LDL-C, and TG levels were determined from fasting whole blood and plasma samples taken soon after admission. The HbA1c, UA, and C-reactive protein (CRP) levels were measured from plasma samples taken at admission. Any history of cerebral infarction or atrial fibrillation resulting in anti-platelet or anti-coagulant therapy prior to admission was recorded. Current medications were confirmed by pharmacists who checked all medications that patients brought to the hospital. Statins were classified as strong statins (atorvastatin, pravastatin, and simvastatin) or standard statins (fluvastatin, pitavastatin, and rosuvastatin). Body mass index (BMI) and laboratory data from a year before admission, including the HDL-C, LDL-C, TG, HbA1c, UA, and CRP levels, were also recorded.

Coronary angiography and evaluation of the stenotic lesion

Cardiac catheterization was performed via a femoral or brachial artery using a 6- or 7-Fr sheath and catheters. After injection of isosorbidedinitrate (2 mg) into the coronary artery, angiography was performed using the AXIOM Artis dTA system (Siemens, Munich, Germany). The angiograms were retrospectively reviewed for this study, and all quantitative angiographic measurements were performed by the same physician who was blinded to the patient details. The percent stenosis was calculated based on the diameter of the culprit lesion and the reference diameter of the adjacent normal vessel. Evaluation of the target lesion by intravascular ultrasonography (Visiwave or Intrafocus II, Terumo, Tokyo, Japan) was attempted prior to PCI in all patients. The intravascular diameter measured by intravascular ultrasonography was used to choose appropriate stent and balloon sizes. Successful coronary stenting was defined as a minimum stenosis diameter of < 10% without major in-hospital complications [15]. Successful balloon angioplasty was defined as a minimum stenosis diameter of < 50% with final TIMI flow grade 3 and no side branch loss, flow-limiting dissection, or angiographic thrombus [15].

Statistical analysis

Continuous data are presented as mean ± SD or number (%). Comparisons of the admission data between the < 1-year and > 1-year groups were performed using the unpaired t test for parametric data or the Mann-Whitney U test for non-parametric data. Non-parametric data, such as the number of patients, were compared between the two groups using the χ² test. Comparisons within the same group were performed using the paired t test for parametric data, or the Wilcoxon signed rank test for non-parametric data. Pearson’s correlation coefficient was used to analyze correlations between different lipid parameters including the HDL-C, LDL-C, and TG levels, or between lipid parameters and other variables associated with CVD such as the HbA1c, UA, and CRP levels. A value of P < 0.05 was considered to indicate a statistically significant association on univariate analysis. As there were significant correlations between the LDL-C and TG levels and between the HbA1c and TG levels in the < 1-year group, the relationship of each variable with the LDL-C and HbA1c levels in this group was determined using multivariate stepwise linear regression analysis. Multicollinearity was assessed using the variance inflation factor (VIF). A VIF exceeding 10 indicates serious multicollinearity, and a value greater than 4 may be a cause for concern. The variables that were found to be significantly associated on univariate analyses (age, BMI, and HDL-C, LDL-C, TG, HbA1c, UA, and CRP levels) were included in the multivariate stepwise linear regression analyses, with a value of P < 0.05 considered statistically significant. The data at 1 year before admission (including BMI and the HDL-C, LDL-C, TG, HbA1c, UA, and CRP levels) were compared between the two groups as described above. For these data, Pearson’s correlation coefficients were also calculated. All analyses were performed using SPSS version 21.0J for Windows (SPSS, Chicago, IL).

Results

The characteristics of patients in the < 1-year and > 1-year groups are shown in Table 1. Patients in the < 1-year group were significantly younger (57.6 ± 11.9 years vs. 76.6 ± 9.1 years, P < 0.01), had a significantly higher BMI (27.22 ± 4.20 kg/m² vs. 24.60 ± 4.65 kg/m², P < 0.05), and were more likely to be male (94% vs. 70%, P < 0.05) than patients in the > 1-year group. There were no significant differences in infarct type, coronary risk factors, or associated conditions between the two groups, except that the proportion of current smokers was significantly higher in the < 1-year group (61% vs. 17%, P < 0.01). Patients in the < 1-year group were significantly less likely to be taking aspirin (17% vs. 57%, P < 0.01) or a calcium antagonist (17% vs. 57%, P < 0.01), and were signifi-
cantly more likely to be taking a strong statin (89% vs. 48%, P < 0.01) or rosuvastatin (44% vs. 15%, P < 0.05) than patients in the > 1-year group. Review of medications (other than statins) initiated within 1 year before admission showed that angiotensin-receptor blockers and sulfonylureas were initiated in two patients in the < 1-year group, and calcium antagonists, angiotensin-receptor blockers, and sulfonylureas were initiated in five patients in the > 1-year group.

Laboratory data on admission including the HDL-C, LDL-C, TG, HbA1c, UA, and CRP levels, locations of culprit lesions, and PCI procedures are shown in Table 2. The UA level was significantly higher in the < 1-year group than in the > 1-year group (5.81 ± 0.85 mg/dL vs. 5.05 ± 1.17 mg/dL, P < 0.05). PCI was unsuccessful in three patients in the > 1-year group, because the guidewire or the balloon could not be advanced through the stenosis. The locations of culprit lesions and the PCI procedures were not significantly different between the two groups. The only significant change in laboratory data between a year before admission and admission in either group was a significant decrease in the LDL-C level in the < 1-year group (P < 0.01).

Table 2. Comparisons of Laboratory Data, Culprit Lesions, and PCI Procedures at Admission

| Laboratory data          | < 1-year statin therapy (n = 18) | > 1-year statin therapy (n = 46) | P   |
|--------------------------|---------------------------------|---------------------------------|-----|
| HDL-C (mg/dL)            | 48.9 ± 8.8                      | 49.1 ± 13.4                     | 0.565|
| LDL-C (mg/dL)            | 124.8 ± 32.0                    | 111.6 ± 29.5                    | 0.122|
| TG (mg/dL)               | 186.1 ± 114.0                   | 133.7 ± 79.4                    | 0.064|
| HbA1c (%)                | 6.82 ± 1.7                      | 6.65 ± 1.26                     | 0.590|
| Uric acid (mg/dL)        | 5.81 ± 0.85*                    | 5.05 ± 1.17*                    | 0.016*|
| CRP (mg/dL)              | 0.17 ± 0.14                     | 0.21 ± 0.19                     | 0.421|

Culprit lesion

| RCA                      | 4 (22)                          | 14 (30)                         | 0.511|
| LAD                      | 12 (67)                         | 20 (44)                         | 0.095|
| LCX                      | 2 (11)                          | 12 (26)                         | 0.168|
| % Stenosis               | 88.4 ± 9.1                      | 88.2 ± 7.4                      | 0.828|

PCI procedure

| POBA alone              | 1 (6)                           | 3 (7)                           | 0.687|
| Stenting                | 17 (94)                         | 40 (86)                         | 0.358|
| Bare-metal stent        | 4 (22)                          | 11 (24)                         | 0.583|
| Drug-eluting stent      | 13 (72)                         | 29 (63)                         | 0.487|
| Mean stent diameter (mm)| 3.23 ± 0.50                     | 3.29 ± 0.44                     | 0.693|
| Mean stent length (mm)  | 21.6 ± 5.8                      | 20.7 ± 4.0                      | 0.781|
| Unsuccessful PCI        | 0 (0)                           | 3 (7)                           | 0.364|

Values are n (%) or mean ± SD. *P < 0.05. HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; HbA1c: hemoglobin A1c; CRP: C-reactive protein; RCA: right coronary artery; LAD: left anterior descending branch; LCX: left circumflex branch; POBA: plain old balloon angioplasty.

Correlations between variables

Although the initial comparisons did not show significant differences in laboratory data between the < 1-year and > 1-year groups, the specific correlations that could be affected by statin therapy were investigated further. Interestingly, in the < 1-year group, there were significant correlations between the LDL-C and TG levels (r = 0.649, P = 0.004), and between the HbA1c and TG levels (r = 0.552, P = 0.018) (Fig. 1a, b), but there were no significant correlations among other background characteristics including age, BMI, and HDL-C, UA, and CRP levels. Multivariate stepwise linear regression analyses also showed significant associations between the LDL-C and TG levels, and between the HbA1c and TG levels (Table 3). There was no evidence of multicollinearity (the VIF for independent variables was < 2.0). The multiple regression coefficient (R) and coefficient of determination (R²) were 0.649 and 0.421 for the association between the LDL-C and TG levels, and 0.552 and 0.304 for the association between the HbA1c and TG levels, respectively. In the > 1-year group, there were no significant correlations between different lipid parameters including the HDL-C, LDL-C and TG levels, or between lipid parameters and other variables associated with CVD (Fig. 1c, d).

BMI and laboratory data a year before admission, including the HDL-C, LDL-C, TG, HbA1c, UA and CRP levels, were analyzed in the same manner as admission data (< 1-year group: n = 17, > 1-year group: n = 37) (Table 4). The BMI and LDL-C level a year before admission were significantly higher in the < 1-year group than in the > 1-year group, reflecting the
absence of statin therapy in the < 1-year group. The UA level a year before admission was also significantly higher in the < 1-year group than in the > 1-year group, showing the same pattern as on admission. Comparisons of data between a year before admission and admission within each group showed that the LDL-C level was significantly higher a year before admission than at admission in the < 1-year group (P < 0.01). There were no significant correlations between different lipid parameters including the HDL-C, LDL-C and TG levels, or between lipid parameters and other variables associated with CVD, in either group. In particular, the TG level was not correlated with the LDL-C or HbA1c level in either group.

**Discussion**

This study focused on patients with onset of ACS despite statin therapy to treat dyslipidemia and lower the CVD risk. Among the 64 patients taking statins who were admitted with ACS, 18 had started statin therapy within the past year. The < 1-year group had a significantly younger age, higher proportion of males, higher BMI, and higher proportion of current smokers.

**Table 3.** Multivariate Stepwise Linear Regression Analyses for Factors Associated With the LDL-C and HbA1c Levels in Patients With Onset of ACS < 1 Year After the Initiation of Statin Therapy

| Factors associated with LDL-C level | Independent variable | B (95% CI) | β | t | P     |
|------------------------------------|----------------------|------------|---|---|-------|
| TG                                 | 0.18 (0.07 - 0.30)   | 0.649      | 3.413 | 0.004 |

| Factors associated with HbA1c level | Independent variable | B (95% CI) | β | t | P     |
|------------------------------------|----------------------|------------|---|---|-------|
| TG                                 | 0.009 (0.002 - 0.015) | 0.552      | 2.646 | 0.018 |

B: non-standardized regression coefficient; CI: confidence interval; β: standardized regression coefficient.
these results indicate that the initiation of statin therapy may not have had much effect on the TG level during this period. Interestingly, there was no significant correlation between the TG and LDL-C levels in the < 1-year group, suggesting that older male smokers with persistent hypertriglyceridemia and low LDL-C levels after the initiation of statin therapy may affect the correlation between the TG and LDL-C levels. As the LDL-C level is measured by the β-quantification method at our institution, IDL-cholesterol is included in the LDL-C level [25]. The linear correlation between the TG and LDL-C levels in the < 1-year group may therefore reflect changes in the lipid compositions of lipoproteins, resulting in formation of TG-rich or TG-saturated LDL and IDL with decreased cholesterol content. In addition, the higher proportion of patients taking strong statins in the < 1-year group may have resulted in a greater decrease in cholesterol content and greater increase in TG content in LDL and IDL. This remains speculative, because the TG and cholesterol levels in LDL and IDL were not measured in this study. But the results of a previous study showing that high-dose administration of atorvastatin did not induce a significant reduction in TG content of LDL [26], support our hypothesis and thus an increased TG content of LDL or IDL may be associated with onset of ACS early after the initiation of statin therapy. Previously reported data suggest that higher TG level may increase the risk of CVD partly because of the accompanying burden of atherogenic remnant particles, small dense LDL, reduced HDL-C, and a high frequency of insulin resistance [27]. The present study also found a stronger correlation between the HbA1c and TG levels compared to a previous study [28]. This finding suggests that statin therapy may increase the influence of TG on glycometabolism, but the underlying mechanisms are currently unknown.

Taken together, detection of a correlation between the LDL-C and TG levels may be a novel predictive marker for onset of ACS early after the initiation of statin therapy. Our findings also suggest that older male smokers with persistent hypertriglyceridemia and low LDL-C levels after the initiation of statin therapy may have a high risk of ACS onset. However, effective treatment for reducing the CVD risk by regulating the lipid compositions of lipoproteins, resulting in formation of TG-rich or TG-saturated LDL and IDL with decreased cholesterol content. In addition, the higher proportion of patients taking strong statins in the < 1-year group may have resulted in a greater decrease in cholesterol content and greater increase in TG content in LDL and IDL. This remains speculative, because the TG and cholesterol levels in LDL and IDL were not measured in this study. But the results of a previous study showing that high-dose administration of atorvastatin did not induce a significant reduction in TG content of LDL [26], support our hypothesis and thus an increased TG content of LDL or IDL may be associated with onset of ACS early after the initiation of statin therapy. Previously reported data suggest that higher TG level may increase the risk of CVD partly because of the accompanying burden of atherogenic remnant particles, small dense LDL, reduced HDL-C, and a high frequency of insulin resistance [27]. The present study also found a stronger correlation between the HbA1c and TG levels compared to a previous study [28]. This finding suggests that statin therapy may increase the influence of TG on glycometabolism, but the underlying mechanisms are currently unknown.

### Table 4. Laboratory Data a Year Before Admission

|                  | < 1-year statin therapy (n = 17) | > 1-year statin therapy (n = 39) | P     |
|------------------|---------------------------------|---------------------------------|-------|
| BMI              | 27.58 ± 4.40*                   | 24.65 ± 4.78                    | 0.035*|
| HDL-C (mg/dL)    | 52.0 ± 10.7                     | 51.0 ± 14.0                     | 0.605 |
| LDL-C (mg/dL)    | 166.5 ± 25.1**                  | 115.9 ± 29.5                    | < 0.001** |
| TG (mg/dL)       | 186.3 ± 68.0                    | 150.2 ± 98.3                    | 0.175 |
| HbA1c (%)        | 6.98 ± 2.15                     | 6.50 ± 1.19                     | 0.872 |
| Uric acid (mg/dL)| 5.75 ± 1.13*                   | 4.95 ± 1.09                     | 0.015*|
| CRP (mg/dL)      | 0.11 ± 0.08                     | 0.22 ± 0.40                     | 0.652 |

Values are n (%) or mean ± SD. *P < 0.05, **P < 0.01. HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; HbA1c: hemoglobin A1c; CRP: C-reactive protein.
the preventive effects of other medications such as aspirin and calcium antagonists on onset of ACS after the initiation of statin therapy could not be analyzed. In addition, the TG, cholesterol, apo B-100, and apo B-48 levels in LDL and IDL were not measured. Although there were significant correlations between the LDL-C and TG levels, and between the HbA1c and TG levels, the effects of these parameters on the onset of ACS and on plaque size and vulnerability are still unclear. It is also unclear whether the correlations between the LDL-C and TG levels, and between the HbA1c and TG levels, in the < 1-year group were also present in the group overall or in specific patients a year after the initiation of statin therapy, because data from before the initiation of statin therapy were not available for the > 1-year group. Prospective cohort studies are needed to further explore these interactions.

Conclusions

Patients with onset of ACS < 1 year after the initiation of statin therapy had a significant linear correlation between the TG and LDL-C levels at admission, which was not observed a year before admission. Patients with onset of ACS < 1 year after the initiation of statin therapy had a higher BMI and were more likely to be male, current smokers, and strong statin users than patients with onset of ACS > 1 year after the initiation of statin therapy. These patients also had persistent hypertriglyceridemia after the initiation of statin therapy despite a significant decrease in the LDL-C level. Further investigation is needed to determine the underlying risk factors in patients with onset of ACS early after the initiation of statin therapy.

Acknowledgement

The authors would like to thank Miss Hisae Kuribara for her secretarial assistance under the financial support provided by Gunma Chuo Hospital.

Competing Interests

The authors declare that they have no competing interests.

Grant Support

None.

Financial Disclosure

All the authors have reported no conflicts of interest.

References

1. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
3. Bellosta S, Ferri N, Arnaboldi L, Bemini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 2000;23(Suppl 2):B72-78.
4. Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, Subramanian SS, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909-917.
5. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-1182.
6. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061-1068.
7. Taguchi I, Oda K, Yoneda S, Kageyama M, Kanaya T, Toyoda S, Abe S, et al. Evaluation of serial changes in tissue characteristics during statin-induced plaque regression using virtual histology-intravascular ultrasound studies. Am J Cardiol. 2013;111(9):1246-1252.
8. Hong YJ, Jeong MH, Choi YH, Ma EH, Ko JS, Lee MG, Park KH, et al. Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/ day. Am J Cardiol. 2010;106(9):1241-1247.
9. Nozue T, Yamamoto S, Tohyama S, Umezawa S, Kunishima T, Sato A, Miyake S, et al. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. Am Heart J. 2012;163(2):191-199 e191.
10. Toi T, Taguchi I, Yoneda S, Kageyama M, Kikuchi A, Tokura M, Kanaya T, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J. 2009;73(8):1466-1472.
11. Shimamoto K, Ando K, Fujita T, Hasebe N, Horiuchi M, Imai Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37(4):253-390.
12. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, et al. Executive summary of the Japan
Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb. 2013;20(6):517-523.

13. Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018-1029.

14. The Japan Diabetes Society. Evidence-based practice guideline for the treatment for diabetes in Japan. 2013. [http://www.jds.or.jp/modules/en/index.php?content_id=44].

15. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-122.

16. Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity. Int J Inflamm. 2011;2011:376909.

17. Robertson JO, Ebrahimi R, Lansky AJ, Mehran R, Stone GW, Lincoff AM. Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). JACC Cardiovasc Interv. 2014;7(4):372-379.

18. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97(11):1029-1036.

19. Li XL, Hong LF, Luo SH, Guo YL, Zhu CG, Sun J, Dong Q, et al. Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease. Lipids Health Dis. 2014;13:73.

20. Ginsberg HN. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006;91(2):383-392.

21. Carrella M, Fong LG, Loguercio C, Del Piano C. Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver. Metabolism. 1999;48(5):618-626.

22. Funatsu T, Goto M, Kakuta H, Suzuki M, Ida M, Nishijima S, Tanaka H, et al. Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. Biochim Biophys Acta. 2002;1580(2-3):161-170.

23. Delsing DJ, Post SM, Groenendijk M, Solaas K, van der Boom H, van Duyvenvoorde W, de Wit EC, et al. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. J Cardiovasc Pharmacol. 2005;45(1):53-60.

24. Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagne C, Couture P. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism. 2008;57(2):246-254.

25. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem. 1995;41(10):1414-1420.

26. Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med. 2011;269(3):333-339.

27. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol. 2009;24(4):345-350.

28. Davidson MB, Hu T, Sain G, Hoar B, Stevenson C, Hoogwerf BJ. The relationship of glycaemic control and triglycerides in patients with diabetes mellitus: a PreCIS Database Study. Diabetes Obes Metab. 2009;11(2):118-122.